Clinical trial
Phase 1b/2, Multicenter, Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies
NCT01416428 is registered in ClinicalTrials.gov with Amgen as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase 1b/2, Multicenter, Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies
- Lead sponsor
- Amgen
- Phase
- Phase 1/2
- Overall status
- Terminated
- Start date
- October 15, 2011
- Completion date
- August 12, 2019
- Enrollment
- 210 (actual)
- Sites
- 19
Conditions
As the registry lists them; a condition with its own page is linked.